BioAtla, Inc. (BCAB) stock
BCABOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.31−0.05 (-3.68%)
Close on Oct 19, 2026Market cap $2.18MP/E –Yield –
BioAtla r&d expenses
Research and development expenses are spending on new products and technology.
BioAtla's R&D Expenses for the twelve months ending Jun 30, 2026 was $25.46M, down 52.9% year over year. For fiscal 2025 it was $43.57M, down 30.9% from the year before. The highest annual figure on record is $103.73M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.57M | -30.9% |
| FY2024 | Dec 31, 2024 | $63.10M | -39.2% |
| FY2023 | Dec 31, 2023 | $103.73M | +30.7% |
| FY2022 | Dec 31, 2022 | $79.35M | +36.2% |
| FY2021 | Dec 31, 2021 | $58.27M | +192.3% |
| FY2020 | Dec 31, 2020 | $19.93M | -23.1% |
| FY2019 | Dec 31, 2019 | $25.92M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.34M | -75.6% |
| Q1 FY2026 | Mar 31, 2026 | $4.58M | -62.9% |
| Q4 FY2025 | Dec 31, 2025 | $8.00M | -31.4% |
| Q3 FY2025 | Sep 30, 2025 | $9.54M | -41.8% |
| Q2 FY2025 | Jun 30, 2025 | $13.68M | -15.5% |
| Q1 FY2025 | Mar 31, 2025 | $12.36M | -34.5% |
| Q4 FY2024 | Dec 31, 2024 | $11.65M | -48.6% |
| Q3 FY2024 | Sep 30, 2024 | $16.40M | -42.3% |
| Q2 FY2024 | Jun 30, 2024 | $16.20M | -47.7% |
| Q1 FY2024 | Mar 31, 2024 | $18.85M | -13.1% |
| Q4 FY2023 | Dec 31, 2023 | $22.67M | +3.7% |
| Q3 FY2023 | Sep 30, 2023 | $28.40M | +43.2% |
| Q2 FY2023 | Jun 30, 2023 | $30.96M | +49.5% |
| Q1 FY2023 | Mar 31, 2023 | $21.70M | +28.2% |
| Q4 FY2022 | Dec 31, 2022 | $21.87M | +33.0% |
| Q3 FY2022 | Sep 30, 2022 | $19.84M | +19.9% |
| Q2 FY2022 | Jun 30, 2022 | $20.71M | +39.5% |
| Q1 FY2022 | Mar 31, 2022 | $16.92M | +62.4% |
| Q4 FY2021 | Dec 31, 2021 | $16.45M | +56.9% |
| Q3 FY2021 | Sep 30, 2021 | $16.55M | +240.3% |
| Q2 FY2021 | Jun 30, 2021 | $14.85M | +408.0% |
| Q1 FY2021 | Mar 31, 2021 | $10.42M | +527.5% |
| Q4 FY2020 | Dec 31, 2020 | $10.49M | – |
| Q3 FY2020 | Sep 30, 2020 | $4.86M | – |
| Q2 FY2020 | Jun 30, 2020 | $2.92M | – |
| Q1 FY2020 | Mar 31, 2020 | $1.66M | – |
See a number that looks wrong?